Overview
Several disorders that cause facial pain can be successfully treated by neurosurgical procedures. It is important to accurately diagnose the disorder and identify the best treatment for each disorder. In the absence of randomized prospective studies, standardized methods of reporting, and standardized outcome criteria, it is difficult to compare the results of various surgical procedures and the different reported series of the same surgical procedure. Nevertheless, several important observations emerge from reviews of the literature and personal experience.
General Observations on Facial Pain
- Accurate diagnosis is required.
- The diagnosis of typical Trigeminal Neuralgia (TGN) is seldom difficult.
- In general, the length of the list of the patients symptoms is directly proportional to the likelihood of treatment failure.
- Medical treatment should be explored before surgery is contemplated.
- There is no successful surgical procedure for treatment of atypical facial pain.
- It is more difficult to treat neuropathic than neuralgic pain.
- Patients with dysesthetic pain seldom respond to ablative surgery.
- There is no single superior treatment for facial pain. The treatment should be individualized. Patients should have access to a broad spectrum of treatment options.
- The results of surgical treatment diminish as facial pain becomes more chronic.
Results for Trigeminal Neuralgia (TGN)
Generalizations regarding treatment of TGN have been presented
in the literature. While some surgeons advocate one procedure for all patients,
others select different surgical procedures for different patients. In the midst
of this controversy, surgeons must not lose sight of the facts and observations
pertaining to the treatment of TGN. Following are some of our observations:
Recognize atypical TGN and status trigeminus
One must distinguish atypical TGN from atypical facial pain. In atypical TGN,
patients report lancinating or brief episodes of sharp or burning pain that
last seconds to minutes and are associated with milder constant aching pain.
Some patients experience status or continuous repeated episodes
of pain of TGN. These patients appear fatigued, often dehydrated, and in constant
severe pain. They frequently report simple continuous pain rather than the typical
episodic pain. Such patients usually require an urgent surgical procedure.
There is no current cure for TGN
All current surgical procedures for TGN are associated with risk of pain recurrence
(1). After successful surgery, pain of TGN can progress to involve other trigeminal
nerve divisions or the contralateral side. In some patients, pain of TGN is
difficult to treat, regardless of what treatment is given. Longstanding chronic
TGN is more difficult to treat. Long-term pain relief is highest after microvascular
decompression (MVD) and percutaneous stereotactic radiofrequency rhizotomy (PSR).
Among the current treatment options, microvascular decompression
(MVD) and percutaneous stereotactic radiofrequency (PSR) rhizotomy have comparable
rates of pain relief that are highest among the available options. In a review
of series of approximately 100 patients or more published in the past 10 years
(2-12), the rates of pain relief calculated were 77% in 7 years for MVD and
75% in 6 years for PSR rhizotomy.
TGN Pain Recurrence
| Procedure |
Follow-up |
Pain-free |
|
| MVD |
7 years |
77% |
| PSR |
6 years |
75% |
| Glycerol rhizotomy |
3 years |
55% |
| Balloon compression |
3 years |
76% |
| Radiosurgery |
1.5 years |
55% |
The timing of pain recurrence is similar for MVD and PSR. In the
series of Barker et al. (6), pain recurrence occurred primarily in the first
2 years after MVD, and then dropped to 2% per year in years 3-5, 1% per year
in years 6-10, and 0.7% per year thereafter. In the authors series (13), pain
recurrence after PSR rhizotomy occurred in 3% of patients per year through the
first 5 years, 1.4% per year in years 6-10, and 0.75% thereafter.
Glycerol rhizotomy and radiosurgery have the highest rates of
pain persistence or recurrence. Pain relief calculated 55% in 3 years for glycerol
rhizotomy (2,14-21). Initial results of 129 patients from three series demonstrate
a pain relief rate of 55% in 1.5 years after radiosurgery (22-24). Balloon compression
has a recurrence rate that is higher than that of MVD and PSR rhizotomy, but
lower than that of glycerol rhizotomy and radiosurgery. Pain relief was calculated
to be 75% in 3 years for balloon compression (2,25,26).
All percutaneous procedures are associated with dysesthesia
Glycerol rhizotomy is frequently reported to be the preferred percutaneous destructive
procedure because of its rare association with dysesthesia (troublesome numbness).
Our review of the literature does not support this hypothesis. In a review of
the results of 1751 patients in 10 series, significant dysesthesias occurred
in 4% of patients after glycerol rhizotomy, in 7% of patients after PSR rhizotomy,
and in 6% of patients after balloon compression. Some surgeons relate the high
incidence of dysesthesia to poor technique, such as the injection of glycerol
without cisternography or injection of large volumes of glycerol during glycerol
rhizotomy (21), production of anesthesia and analgesia during PSR rhizotomy
(1), and prolonged balloon inflation during balloon compression (26). Supporters
of glycerol rhizotomy and balloon compression estimate a lower incidence of
dysesthesia in technically adequate procedures (21). Supporters of PSR rhizotomy
estimate rates of dysesthesia and pain recurrence that are comparable with those
of glycerol rhizotomy and balloon compression if lesions created by PSR produced
hypalgesia only (1).
Contrary to percutaneous destructive procedures, MVD rarely produces
significant facial numbness or dysesthesia. In the authors experience, facial
sensory loss and dysesthesia complicated cases of venous compression or excessive
manipulation of the trigeminal rootlets. The initial results of radiosurgery
demonstrate a rare association with sensory loss and dysesthesia, despite the
fact that the nerve is deliberately injured (23).
Postoperative corneal anesthesia in patients
with V-1 pain is highest after PSR

Among the percutaneous destructive procedures, PSR rhizotomy has
the highest risk of postoperative loss of corneal sensations after surgery for
V-1 pain. PSR rhizotomy differentially affects the small myelinated and unmyelinated
fibers, which mediate the corneal reflex (2). In contrast, balloon compression
differentially affects large myelinated fibers (26). Glycerol has neurolytic
effects on both small and large myelinated fibers (21). In our review of the
literature, the corneal reflex was lost in 6% of PSR rhizotomies, in 5% of glycerol
rhizotomies, and in 1% of balloon compressions. MVD and radiosurgery have been
rarely associated with corneal anesthesia.
Postoperative trigeminal motor weakness is highest
after balloon compression
Balloon compression carries the highest risk of postoperative
trigeminal motor weakness. In a review of the literature, trigeminal weakness
occurred transiently in 19% of patients after PSR rhizotomy, infrequently (1%)
after glycerol rhizotomy, and permanently in 5% after balloon compression. Trigeminal
motor weakness occurred rarely after MVD and radiosurgery. Complications such
as trismus, otalgia, and hyperacusis have not been thoroughly discussed in the
literature and are likely underestimated.
Perioperative morbidity and mortality are
higher after MVD
than after percutaneous destructive procedures
Literature review demonstrates that the perioperative mortality
or serious morbidity (i.e., stroke, hemorrhage, venous sinus occlusion, myocardial
infarction, hydrocephalus), permanent hearing loss or facial palsy, and minor
perioperative complications (i.e., wound dehiscence or infection, cerebrospinal
fluid leak, pseudomeningocele, bacterial and aseptic meningitis, pulmonary complications,
ataxia) were higher after MVD than after percutaneous procedures. After MVD,
serious morbidity or mortality occurred in 1%, permanent hearing loss occurred
in 3%, and minor complications occurred in 16%. The risks are higher in patients
who have an ectatic and tortuous vertebrobasilar system arterial tree (27).
These results do not compare favorably with rates of 0.07% serious morbidity
and mortality, 0.5% serious hearing loss, and 1.3% minor complications for percutaneous
procedures.
Conclusion
All available procedures for TGN have side-effects (+=lowest,
+++=highest)
| Surgery |
Pain recurrence |
Dysesthesia
(numbness) |
Motor
weakness |
Corneal
anesthesia |
Minor
morbidity |
Major
morbidity |
|
| MVD |
+ |
+ |
+ |
+ |
+++ |
+++ |
| PSR |
+ |
+++ |
+ |
+++ |
+ |
+ |
| Glycerol rhizotomy |
+++ |
++ |
+ |
+ |
+ |
+ |
| Balloon compression |
++ |
+++ |
+++ |
+ |
+ |
+ |
| Rhizotomy |
+ |
+++ |
+ |
+++ |
+++ |
+++ |
| Neurectomy |
++ |
+++ |
+ |
+ |
+ |
+ |
| Radiosurgery |
+++ |
+ |
+ |
+ |
+ |
+ |
MVD is highly successful in treating pain of TGN with a relatively
low risk of pain recurrence, dysesthesia, corneal analgesia, and trigeminal
motor weakness; however, one should not overlook the perioperative risks associated
with this surgery, especially in the elderly. MVD may be best suited for healthy
patients, but is not the best procedure for patients in poor medical condition.
Because of the risk of hearing loss, MVD may not be suitable for patients who
have contralateral hearing loss. MVD may also not be the best procedure for
patients who have large, ectatic, and tortuous vertebrobasilar arterial system
because of increased perioperative morbidity.
Percutaneous destructive procedures are appropriate procedures
for the elderly and for those in poor medical condition. Because of its low
pain recurrence rate, PSR
rhizotomy generally seems to be the most appropriate procedure. By avoiding
dense lesions, adverse effects of dysesthesias are greatly reduced. PSR rhizotomy
may not be the best procedure for patients with V-1 pain and patients with pain
distributed over the three trigeminal divisions.
Because glycerol rhizotomy is associated with a high recurrence
rate, the procedure likely requires repetition. Multiple glycerol injections
are associated with a higher risk of failure and adverse effects. During glycerol
rhizotomy, surgeons and patients should be ready to convert the procedure to
PSR rhizotomy if cerebrospinal fluid flow is not obtained. Because of its low
risk of trigeminal motor dysfunction, glycerol rhizotomy is particularly advantageous
for patients with contralateral pain, trigeminal motor weakness, and temporomandibular
joint dysfunction. Glycerol rhizotomy is also appropriate for patients who have
pain over V-1 or the entire face and are not candidates for a posterior fossa
procedure.
Balloon compression seems particularly advantageous for patients
who have V-1 pain and are not good candidates for microvascular decompression.
Alternative procedures for these patients include glycerol rhizotomy, peripheral
nerve section, and radiosurgery.
Other surgical procedures have a role in the treatment of TGN.
Peripheral nerve section is appropriate for elderly patients with V-1 pain or
with bilateral facial pain. Radiosurgery has a role in the treatment of patients
who cannot safely undergo surgical procedures, such as patients who are receiving
anticoagulants.
In summary, the authors conclude that the discipline of treating
TGN should be similar to disciplines of treating other disorders, such as aneurysms,
tumors, and vascular malformations. The discipline entails a multimodality approach
conducted by a team who can offer medical and surgical treatments directed to
the needs of the individual patient.
next>> Recurrent Trigeminal Neuralgia
Sources
Through the Trigeminal Neuralgia Association (TNA), local support groups are available. The support group provides an opportunity for patients and their families to share experiences, receive support, and learn about advances in treatments, pain control, and medications. Additional information is available on the web at www.tna-support.org or facial-neuralgia.org
If you would like information about the Greater Cincinnati Trigeminal Neuralgia Support Group, please call the Mayfield Clinic at (513)569-5290. For support outside Greater Cincinnati, please contact the Trigeminal Neuralgia Association at 800-923-3608.
The following journal articles and books formed the basis of our observations along with our own personal experience. Bibliography listing.
updated: 6.2004
originally published > Tew JM, Taha JM: Therapeutic Decisions in Facial Pain. Clinical Neurosurgery 46:410-431, 2000 |